, Volume 63, Supplement 1, pp 9–22 | Cite as

Central Components of the Analgesic/ Antihyperalgesic Effect of Nimesulide: Studies in Animal Models of Pain and Hyperalgesia

  • Cristina Tassorelli
  • Rosaria Greco
  • Giorgio Sandrini
  • Giuseppe Nappi
Original Research Article


The analgesic action of NSAIDs has been attributed to the peripheral inhibition of prostaglandin synthesis via the blockade of the enzyme cyclo-oxygenase (COX) and prevention of bradykinin and cytokine-induced hyperalgesia via inhibition of the release of tumour necrosis factor-α. However, it is becoming increasingly evident that NSAIDs exert their analgesic effect through several mechanisms. Recent data suggest that significant expression of COX-2 is found in the central nervous system, where COX-2 seems to have, together with nitric oxide, an important role in spinal nociceptive transmission. Nitroglycerin is a nitric oxide donor and induces a hyperalgesic state, partially mediated by central mechanisms. Nimesulide is a preferential COX-2 inhibitor widely used to treat pain.

In this study, we evaluated the analgesic effect of nimesulide in several animal models of pain, intending to provide additional information on the characteristics of the analgesic effect of nimesulide, with specific focus on a possible central component.

Study Design: Nimesulide was compared with vehicle in groups of 4–10 rats that were randomly tested with different models of pain. The experimental design also included study of the effect of nimesulide upon nitroglycerin-induced neuronal activation at central sites. Analysis of variance was used to evaluate the influence of time and treatments. Differences between groups at specific time-points were analysed by post-hoc t-test. A probability level of less than 5% was regarded as significant.

Methods: The analgesic effect of nimesulide (or vehicle) was evaluated in male Sprague-Dawley rats. The animals underwent tail-flick and formalin tests, both performed in baseline conditions and after nitroglycerin-induced hyperalgesia. Two separate groups of rats were treated with nitroglycerin alone or nimesulide followed by nitroglycerin, and their brains were processed for immunocytochemical detection of Fos protein, a marker of neuronal activation.

Results: Nimesulide showed a significant analgesic effect in both the tail-flick and the formalin tests in baseline conditions. In addition, the drug proved effective in counteracting nitroglycerin-induced hyperalgesia in both tests. Brain mapping of nuclei activated by the administration of nitroglycerin showed that nimesulide pretreatment significantly inhibited neuronal activation in several areas, namely the supraoptic nucleus, ventrolateral column of the periaqueductal grey, locus coeruleus, nucleus tractus solitarius and area postrema.

We conclude that nimesulide possesses a strong analgesic and antihyperalgesic activity, the mechanisms of action of which are partly central.


Nitric Oxide Nitroglycerin Nimesulide Nucleus Tractus Solitarius Formalin Test 


  1. 1.
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232–5PubMedGoogle Scholar
  2. 2.
    Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001; 41: 299–332.PubMedCrossRefGoogle Scholar
  3. 3.
    Taiwo YO, Levine JD. Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses. J Neurosci 1998; 8: 1346–9Google Scholar
  4. 4.
    Uda R, Horiguchi S, Ito S, et al. Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, F2 to conscious mice. Brain Res 1990; 510: 26–32PubMedCrossRefGoogle Scholar
  5. 5.
    Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257: 1276–9PubMedCrossRefGoogle Scholar
  6. 6.
    Minami T, Nishihara I, Uda R, et al. Characterization of EP-receptor subtypes involved in allodynia induced by intrathecal administration of prostaglandin E2. Br J Pharmacol 1994; 112: 735–40PubMedCrossRefGoogle Scholar
  7. 7.
    Minami T, Uda R, Horiguchi S. Allodynia evoked by intrathecal administration of prostaglandin E2. Pain 1994; 57: 217–23PubMedCrossRefGoogle Scholar
  8. 8.
    Vanegas H, Schaible H-G. Prostaglandins and cyclooxygenases in the spinal cord. Prog Neurobiol 2001; 64: 327–63PubMedCrossRefGoogle Scholar
  9. 9.
    Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999; 57: 1–164PubMedCrossRefGoogle Scholar
  10. 10.
    Kawabata A, Umeda N, Takagi H. L-Arginine exerts a dual role in nociceptive processing in the brain: involvement of the kyotorphin-Met-enkephalin pathway and NO-cyclic GMP pathway. Br J Pharmacol 1993; 109: 73–9PubMedCrossRefGoogle Scholar
  11. 11.
    Malmberg AB, Yaksh TL. Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain 1993; 54: 291–300PubMedCrossRefGoogle Scholar
  12. 12.
    Wiertelak EP, Furness LE, Watkins LR, et al. Illness-induced hyperalgesia is mediated by a spinal NMDA-nitric oxide cascade. Brain Res 1994; 664: 9–16PubMedCrossRefGoogle Scholar
  13. 13.
    Linden DR, Seybold VS. Spinal neurokinin receptors mediate thermal but not mechanical hyperalgesia via nitric oxide. Pain 2000; 80: 309–17CrossRefGoogle Scholar
  14. 14.
    Hamalainen MM, Lovick TA. Involvement of nitric oxide and serotonin in modulation of antinociception and pressor response evoked by stimulation in the dorsolateral region of the periaqueductal gray matter in the rat. Neuroscience 1997; 80: 821–7PubMedCrossRefGoogle Scholar
  15. 15.
    Aley KO, McCater G, Levine JO. Nitric oxide signaling in pain and nociceptor sensitization in the rat. J Neurosci 1998; 18: 7008–14PubMedGoogle Scholar
  16. 16.
    Gao WC, Ojao JT. Nitric oxide contributes to both spinal nociceptive transmission and its descending inhibition in rats: an immunocytochemical study. Neurosci Lett 1998; 40: 143–6CrossRefGoogle Scholar
  17. 17.
    Ferreira J, Santos AR, Calixtom JB. The role of systemic spinal and supraspinal L-arginine-nitric oxide-cGMP pathway in thermal hyperalgesia caused by intrathecal injection of glutamate in mice. Neuropharmacology 1999; 38: 835–42PubMedCrossRefGoogle Scholar
  18. 18.
    Urban MO, Gebhart GF. Supraspinal contribution to hyperalgesia. PNAS 1999; 96: 7687–92PubMedCrossRefGoogle Scholar
  19. 19.
    Dawson TM, Snyder SH. Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J Neurosci 1994; 14: 5137–53Google Scholar
  20. 20.
    Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995; 57: 683–706PubMedCrossRefGoogle Scholar
  21. 21.
    Coderre TJ. The role of excitatory amino acid receptors and intracellular messengers in persistent nociception after tissue injury in rat. Molec Biol 1993; 7: 229–46Google Scholar
  22. 22.
    Coderre TJ, Yashpal K. Intracellular messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model. Eur J Neurosci 1994; 6: 1328–34PubMedCrossRefGoogle Scholar
  23. 23.
    Kitto KF, Haley JE, Wilcox GL. Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse. Neurosci Lett 1992; 148: 1–5PubMedCrossRefGoogle Scholar
  24. 24.
    Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998; 391: 281–5PubMedCrossRefGoogle Scholar
  25. 25.
    McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9–43PubMedCrossRefGoogle Scholar
  26. 26.
    Ferreira SH. The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs 1993; 46: 1–9PubMedCrossRefGoogle Scholar
  27. 27.
    Kaube H, Hoskin HL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 1993; 33: 541–4PubMedCrossRefGoogle Scholar
  28. 28.
    Sandrini M, Vitale G, Pini LA. Central antinociceptive activity of acetylsalicylic acid is modulated by brain serotonin receptor subtypes. Pharmacology 2002; 65: 193–7PubMedCrossRefGoogle Scholar
  29. 29.
    Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs 1996; 52 Suppl. 5: 13–23PubMedCrossRefGoogle Scholar
  30. 30.
    O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156–60PubMedCrossRefGoogle Scholar
  31. 31.
    Davis R, Brodgen RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431–54Google Scholar
  32. 32.
    Tassorelli C, Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res 1995; 682: 167–78PubMedCrossRefGoogle Scholar
  33. 33.
    Tassorelli C, Joseph SA, Buzzi G, et al. The effect on the central nervous system of nitroglycerin —putative mechanisms and mediators. Prog Neurobiol 1999; 57: 606–24CrossRefGoogle Scholar
  34. 34.
    Tassorelli C, Joseph SA, Nappi G. Neurochemical mechanisms of nitroglycerin-induced neuronal activation. Neuropharmacology 1997; 10: 1417–24CrossRefGoogle Scholar
  35. 35.
    Tassorelli C, Greco R, Morocutti A, et al. Nitric oxide-induced neuronal activation in the central nervous system as an animal model for migraine: mechanisms and mediators. Funct Neurol 2001; 16 Suppl 4: 69–76PubMedGoogle Scholar
  36. 36.
    Jones MG, Lever I, Bingham S, et al. Nitric oxide potentiates response of trigeminal neurones to dural or facial stimulation in the rat. Cephalalgia 2001; 21: 643–55PubMedCrossRefGoogle Scholar
  37. 37.
    Reuter U, Chiarugi A, Bolay H, et al. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002; 51: 507–16PubMedCrossRefGoogle Scholar
  38. 38.
    Tassorelli C, Greco R, Wang D, et al. Nitroglycerin induces hyperalgesia in rats — a time-course study. Eur J Pharmacol 2003; 464: 159–62PubMedCrossRefGoogle Scholar
  39. 39.
    D'Armour FE, Smith DC. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1980; 72: 74–9Google Scholar
  40. 40.
    Tjolsen A, Berge OG, Hunskaar S, et al. The formalin test: an evaluation of the method. Pain 1992; 51: 5–17PubMedCrossRefGoogle Scholar
  41. 41.
    Hao S, Takahata O, Iwasaki H. Intrathecal endorphin-1 produces antinociceptive activities modulated by alpha 2-adrenoceptors in the rat tail flick, tail pressure and formalin tests. Life Sci 2000; 66: 195–204CrossRefGoogle Scholar
  42. 42.
    Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature 1983; 306: 686–8PubMedCrossRefGoogle Scholar
  43. 43.
    Sengupta S, Velpandian T, Sapra P, et al. Comparative analgesic efficacy of nimesulide and diclofenac gels after topical application on the skin. Skin Pharmacol Appl Skin Physiol 1998; 11: 273–8PubMedCrossRefGoogle Scholar
  44. 44.
    Gupta SK, Bansal P, Bhardwaj RK, et al. Comparative antinociceptive, anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination. Pharmacol Res 2000; 41: 657–62PubMedCrossRefGoogle Scholar
  45. 45.
    Matsumoto H, Naraba H, Ueno A, et al. Inhibition of cyclooxygenase-2 causes an enhancement of writhing response in mice. Eur J Pharmacol 1998; 352: 47–52PubMedCrossRefGoogle Scholar
  46. 46.
    Bianchi M, Broggini M. Anti-hyperalgesic effects of nimesulide: studies in rats and humans. Int J Clin Pract 2002; 128 Suppl. 1: 11–9Google Scholar
  47. 47.
    Islas-Cadena M, Banuelos P, Granados-Soto V. Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceptive effect of nimesulide. J Pharmacol Toxicol Metab 1999; 42: 87–92CrossRefGoogle Scholar
  48. 48.
    Torfgard K, Ahnler J, Axelsson KL, et al. Tissue distribution of glyceryl trinitrate and the effect on cGMP levels in rat. Pharmacol Toxicol 1989; 64: 369–72PubMedCrossRefGoogle Scholar
  49. 49.
    Mashimo T, Pak M, Choe H, et al. Effects of vasodilators guanethidine, nicardipine, nitroglycerin, and prostaglandin E1 on primary afferent nociceptors in humans. J Clin Pharmacol 1997; 37: 330–5PubMedGoogle Scholar
  50. 50.
    Sandrini G, Tassorelli C, Proietti Cecchini A, et al. Effects of nimesulide on nitric oxide-induced hyperalgesia in humans — a neurophysiological study. Eur J Pharmacol 2002; 450: 259–62PubMedCrossRefGoogle Scholar
  51. 51.
    Taniguchi Y, Yokoyama K, Inui K, et al. Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide. Eur J Pharmacol 1997; 330: 221–9PubMedCrossRefGoogle Scholar
  52. 52.
    Taniguchi Y, Ikesue A, Yokoyama K, et al. Selective inhibition by nimesulide, a novel non-steroidal anti-inflammatory drug, of prostaglandin endoperoxidase synthase-2 activity in vitro. Pharmacol Sci 1995; 1: 173–5Google Scholar
  53. 53.
    Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneimittelforschung 1995; 45: 1096–8PubMedGoogle Scholar
  54. 54.
    Beiche F, Geisslinger G, Goppelt-Struebe M. Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. Inflamm Res 1988; 47: 482–7CrossRefGoogle Scholar
  55. 55.
    Maihofner C, Tegeder I, Euchenhofer C, et al. Localization and regulation of cyclo-oxygenase-1 and -2 and neuronal nitric oxide synthase in mouse spinal cord. Neuroscience 2000; 101: 1093–108PubMedCrossRefGoogle Scholar
  56. 56.
    Tegeder I, Niederberger E, Vetter G, et al. Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behavior and prostaglandin E2 release in the spinal cord. J Neurochem 2001; 79: 777–86PubMedCrossRefGoogle Scholar
  57. 57.
    Torres-Lopez JE, Ortiz M, Castaneda-Hernandez G, et al. Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. Life Sci 2002; 70: 1669–76PubMedCrossRefGoogle Scholar
  58. 58.
    Euchenhofer C, Maihofner C, Brune K, et al. Differential effect of selective cyclooxygenase-2 (COX-2) inhibitor NS 398 and diclofenac on formalin-induced nociception in the rat. Neurosci Lett 1998; 248: 25–8PubMedCrossRefGoogle Scholar
  59. 59.
    Mazario J, Gaitan G, Herrero JF. Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes. Neurpharmacology 2001; 40: 937–46CrossRefGoogle Scholar
  60. 60.
    Yaksh TL, Dirig DM, Conway CM, et al. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001; 21: 5847–53PubMedGoogle Scholar
  61. 61.
    Yamamoto T, Nozaki-Taguchi N. The role of cyclooxygenase-1 and -2 in the rat formalin test. Anesth Analg 2002; 94: 962–7PubMedCrossRefGoogle Scholar
  62. 62.
    Coderre TJ, Katz J, Vaccarino AL, et al. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993; 52: 259–85PubMedCrossRefGoogle Scholar
  63. 63.
    Sasaki M, Tohda C, Kuraishi Y. Region-specific increase in glutamate release from dorsal horn of rats with adjuvant inflammation. Neuroreport 1998; 9: 3219–22PubMedCrossRefGoogle Scholar
  64. 64.
    Sluka KA, Willis WD. Increased spinal release of excitatory amino acids following intradermal injection of capsaicin is reduced by a protein kinase G inhibitor. Brain Res 1998; 798: 281–6PubMedCrossRefGoogle Scholar
  65. 65.
    DeGroot J, Zhow S, Carlton SM. Peripheral glutamate release in the hind paw following low and high intensity sciatic stimulation. Neuroreport 2000; 14: 497–502CrossRefGoogle Scholar
  66. 66.
    Lawand NB, McNearney T, Westlund KN. Amino acid release into the knee joint: key role in nociception and inflammation. Pain 2000; 86: 69–74PubMedCrossRefGoogle Scholar
  67. 67.
    Ferreira SH, Lorenzetti BB. Intrathecal administration of prostaglandin E2 causes sensitization of the primary afferent neuron via the spinal release of glutamate. Inflamm Res 1996; 45: 499–502PubMedCrossRefGoogle Scholar
  68. 68.
    Kawamata T, Omote K. Activation of spinal N-methyl-D-aspartate receptor stimulates a nitric oxide/cyclic guanosine 3,5-monophosphate/glutamate release cascade in nociceptive signaling. Anesthesiology 1999; 91: 1415–24PubMedCrossRefGoogle Scholar
  69. 69.
    Dickenson AH. A cure for wind-up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990; 11: 307–9PubMedCrossRefGoogle Scholar
  70. 70.
    Minami T, Nishihara I, Uda R, et al. Involvement of glutamate receptors in allodynia induced by prostaglandin E2 and F2 alpha injected into conscious mice. Pain 1994; 57: 225–31PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Cristina Tassorelli
    • 1
  • Rosaria Greco
    • 1
  • Giorgio Sandrini
    • 1
  • Giuseppe Nappi
    • 1
    • 2
  1. 1.Laboratories of Integrative Autonomic Systems and Neurophysiology of Pain, IRCCS Institute of Neurology C. Mondino FoundationUniversity Center for Adaptive Disorders and Headache (UCADH)PaviaItaly
  2. 2.Department of NeurologyUniversity La SapienzaRomeItaly

Personalised recommendations